Objective To explore the application of metagenomic next-generation sequencing(mNGS)in gene polymorphisms of drug targets in pneumocystis jiroveci.Method A total of 76 AIDS patients with suspected pneumo-cystis jiroveci pneumonia(PCP)in Jiujiang Third people's Hospital were enrolled as the research objects between Novem-ber 2018 and November 2023.According to mNGS results,patients were divided into PCP infection group(n=27)and non-infection group(n=49).The gene polymorphisms of drug targets were detected by polymerase chain reaction(pCR).Result In the 76 patients with suspected PCP,mNGS results showed that there were 27 cases(35.53%)with PCP.CD4+in non-infection group was significantly higher than that in PCP infection group(p<0.05).In dihydrop-teroate synthetase(DHpS)gene,there were2 strains(7.41%)with drug-resistant mutation.In dihydrofolate reductase(DHFR)gene,there was 1 strain(3.70%)with non-synonymous mutation at base 188 locus and 11 strains(40.74%)with synonymous mutation at base 312 locus,and there was no one strain with with drug-resistant mutation.In cytochrome b(CYB)gene,there were 5 genotypes(CYB1,CYB2,CYB,CYB,CYB10),and there was no mutations of drug-relat-ed targets.Conclusion pCR amplification combined with mNGS could detect drug target genes of pneumocystis while de-tecting pneumocystis jiroveci so as to select targeted therapeutic regimens.
维普
万方数据